Small Molecules

Lilly Announces New $4.5 Billion Site

Eli Lilly and Company (Lilly) recently announced a $4.5 billion (€4.07 billion) investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development.

SK Pharmteco to Expand Production in South Korea

South Korean contract development and manufacturing organization (CDMO) SK Pharmteco announced a major expansion of its small molecule and peptide production capabilities with a $260 million investment to construct a new facility in Sejong, South Korea.

AbbVie to Build New Biologics Manufacturing Site in Singapore

Last week, AbbVie broke ground on a new Singapore manufacturing facility located in Singapore's Tuas Biomedical Park. The company will invest $223 million in the site which will add 24,000 l of biologics drug-substance capacity to AbbVie's global manufacturing network and support current products as well as emerging immunology and oncology compounds within its pipeline.

Integrated Drug Development Models

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.

Managing Supply for Complex Biotherapeutics

Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process and access to a range of large- and small-molecule manufacturing assets.

Innovative Anti-Infectives

A Wide Spectrum of Contract Services

Cambrex Invests in Swedish cGMP Facility

Bioelectronic Medicines: A New Type of Personalization

Astellas Pays €800 Million for Ogeda

Proteros Signs Second Oncology Collaboration with MSD

The Winning Formula

GSK and Fimbrion Link on UTI Drug

Trends in Chemical & Pharmaceutical Research

Cambrex Announces Investment & Expansion

Opportunities in Drug Development and Manufacturing

Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.

The Winning Formula

After Pharma’s Patent Cliff

Blueprint and Roche in Cancer Immunotherapy Deal

AstraZeneca and Sanofi Swap Compounds

Chances and Hurdles for Biosimilars

Sanofi and Lead Pharma Seal Autoimmune R&D Pact

Bristol-Myers Squibb Completes Amira Acquisition

Bristol-Myers to Acquire Amira Pharma For $325 Million